Back to Lung Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03366480

NCT03366480
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You are 18 years of age or older
  • You are willing and able to give your written agreement to take part in the trial
  • You have been diagnosed with advanced, returning, or spread endometrial (womb) cancer of any type except carcinosarcoma or leiomyosarcoma; OR you have a confirmed diagnosis of squamous non-small cell lung cancer at an advanced or late stage (excluding certain mixed or rare types)
  • You have tumour tissue available for testing — either a stored sample from the last 6 months or a new biopsy
  • In the doctor's opinion, you are expected to live for at least 12 weeks
  • You have at least one measurable tumour that can be tracked to see if the treatment is working
  • Your general health and ability to carry out daily activities is rated at a good level (ECOG score of 0 or 1)
  • You agree to use two reliable forms of contraception during the trial and for 6 months after the last dose of the study drug (applies to both men and women who could father or become pregnant)
  • Your blood counts, liver function, and kidney function all meet the required levels as shown in blood tests (confirm specific values with trial site)
  • Any side effects from previous cancer treatments have largely cleared up

Who may not be able to join:

  • You have previously been treated with a drug that targets a specific cell signalling pathway called PI3K/Akt/mTOR (confirm with trial site)
  • You received chemotherapy as a preventative or supportive treatment within the last 6 months
  • You have brain tumours that are causing symptoms; those with treated, symptom-free brain tumours may still be considered if stable on medication for at least 1 month and without significant nerve damage
  • You have stomach or gut problems that prevent you from swallowing tablets or absorbing medication properly
  • You are currently pregnant or breastfeeding (a pregnancy test will be required within 7 days before starting treatment)
  • You have had a heart attack within the last 12 months, or have significant heart failure, unstable chest pain, or a heart rhythm problem requiring medication
  • You have high blood pressure that is not currently being controlled (those whose blood pressure is managed with medication may still be eligible)
  • You have an active, uncontrolled hepatitis B, hepatitis C, or HIV infection
  • You have another medical or mental health condition that, in the doctor's opinion, could interfere with treatment or put you at risk

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Ability Pharmaceuticals SL
Registry
clinicaltrials_gov
Start date
1 December 2016
Est. completion
1 June 2020

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Emergent Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov